Trevi Therapeutics (NASDAQ:TRVI) Stock Price Expected to Rise, B. Riley Financial Analyst Says

Trevi Therapeutics (NASDAQ:TRVI) had its target price increased by equities research analysts at B. Riley Financial from $21.00 to $31.00 in a research note issued on Monday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the stock. B. Riley Financial’s target price would indicate a potential upside of 70.52% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Stifel Nicolaus set a $30.00 target price on shares of Trevi Therapeutics in a research report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Friday. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, May 20th. D. Boral Capital reiterated a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a research report on Friday, April 17th. Finally, Wall Street Zen raised Trevi Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.91.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $18.18 on Monday. The firm has a fifty day moving average of $15.96 and a 200-day moving average of $13.40. The company has a market cap of $2.58 billion, a price-to-earnings ratio of -56.81 and a beta of 1.00. Trevi Therapeutics has a 1 year low of $6.55 and a 1 year high of $20.22.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Analysts predict that Trevi Therapeutics will post -0.47 EPS for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Nan Fung Trinity HK Ltd. increased its stake in Trevi Therapeutics by 924.2% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 917,450 shares of the company’s stock valued at $11,486,000 after buying an additional 827,875 shares during the period. F m Investments LLC bought a new stake in shares of Trevi Therapeutics during the 4th quarter worth about $3,023,000. Pictet Asset Management Holding SA lifted its stake in shares of Trevi Therapeutics by 13,507.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,532,013 shares of the company’s stock worth $19,181,000 after acquiring an additional 1,520,754 shares during the period. Candriam S.C.A. acquired a new stake in shares of Trevi Therapeutics in the 1st quarter worth approximately $9,229,000. Finally, Comerica Bank boosted its holdings in shares of Trevi Therapeutics by 19,481.8% in the fourth quarter. Comerica Bank now owns 83,027 shares of the company’s stock valued at $1,039,000 after acquiring an additional 82,603 shares in the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.